Chen Bihua

Chen Bihua discloses dealings in 7 companies, chiefly MoonLake Immunotherapeutics, BridgeBio Oncology Therapeutics, Inc. and Erasca, Inc. Between 22 October 2020 and 17 September 2026, the trades on record add up to 26 filings.

On the open market, the record shows 10 purchases worth €75.2M and 2 sales worth €3.7M. On balance, insiders were net buyers of €71.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 3 share grants and 1 option exercise. So far in 2026, the count stands at 1 purchase and no sales.

In size, the median ticket on the buying side is €3.9M. Clusters matter here: 3 out of 9 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 80% of cases; the median change was +8.7%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 8 October 2026: a transaction, in Mingfa Group (International) Co. Ltd. The last purchase on record was published on 10 August 2026, which is 72 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.